Detail akcie Apollomics Rg-A online

Business Summary: Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Apollomics Inc revenues increased from $0K to $8.5M. Net loss decreased 64% to $12.5M. Revenues reflect Engaging in research and development of biologics of oncolog segment increase from $1.7M to $8.6M. Lower net loss reflects Research and development expenses - Bal decrease of 64% to $3.5M (expense), Labor & Related Expenses in R&D decrease of 91% to $308K (expense).